Your session is about to expire
← Back to Search
Benralizumab for Cancer-related Skin Side Effects
Study Summary
This trial will test whether benralizumab is a safe and effective treatment to reduce skin side effects from cancer treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 220 Patients • NCT02075255Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treating my skin rash or itchiness with medication for at least a week.I have not received any live vaccines in the last 30 days.I have received treatments like ipilimumab or pembrolizumab.My liver enzymes are within the required range.I have a skin reaction from treatment and my blood test shows high eosinophils.I am currently taking or have taken specific targeted cancer therapies.I am planning to receive or am currently on alpelisib or immunotherapy/targeted therapy for my condition.I am taking alpelisib for a growth disorder linked to PIK3CA.I am fully active or can carry out light work.I can receive shots under my skin.I received a vaccine, but it was not within 1 week of any trial treatment.My blood counts meet the required levels without transfusions.I have had both ovaries and fallopian tubes surgically removed.I am a woman who cannot have children.I have had a hysterectomy.I have had both of my fallopian tubes surgically removed.My cancer has been confirmed by lab tests.I plan to keep taking my current cancer medication.My kidney function, measured by creatinine levels, is within the normal range.I have not had a menstrual period for at least one year.You have a condition called bullous dermatitis.You have eczema, a skin condition.You have had an allergic reaction in the past to the study medication.I have a worm infection diagnosed in the last 24 weeks that hasn't improved with standard treatment.I have a flat or slightly raised spotted rash.You have a skin condition called urticaria (hives).You have had a severe allergic reaction to biologic therapy in the past.I am not using new creams or medications for itchiness or rash.I am between 18 and 85 years old.My bone marrow, liver, and kidneys are functioning well.I am a woman eligible for this trial based on specific criteria.I am a woman who can become pregnant and meet specific health conditions.I have had both of my ovaries surgically removed.I am taking 20mg or more of prednisone daily.I have used anti-IL-5 drugs or biologics for asthma.I have HIV or hepatitis B/C that needs antiviral treatment.I do not have an infection that could interfere with the study treatment.I am not pregnant or breast-feeding.I experience severe itching.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who meets the eligibility requirements for participating in this research?
"The study's aim is to include 30 individuals that have solid carcinoma and are between 18-85 years old."
Are there any similar studies to this one that use Benralizumab?
"First researched in 2014 at the National Institutes of Health Clinical Center, Benralizumab has completed 31 studies with 20 more active and ongoing. Most recent research is conducted out of Harrison, New jersey."
Are there any current openings for this type of trial you're conducting?
"The clinical trial is still recruiting patients, according to the information available on clinicaltrials.gov. The study was originally posted on September 16th, 2020 and was last edited on September 14th, 2020. They are looking for 30 participants at 5 different sites."
Does this experiment only consider those under 35 years old?
"This study allow for patients that are between 18-85 years old, as long as they meet the other eligibility requirements."
When was Benralizumab cleared by the FDA?
"Benralizumab is a Phase 2 medication, meaning that while there is some evidence suggesting it is safe, there is no data to support its efficacy."
Is this study taking place across many hospitals in North America?
"Presently, this trial is being conducted at 5 different locations. While Harrison, Basking Ridge and Hauppauge are the closest to the city, other participating centres are located in 5 additional cities. If you choose to participate in this study, it would be most convenient for you to select a site that is close to your home to cut down on travel time requirements."
How many individuals are being included in this trial?
"The clinical trial is currently ongoing, as noted by the information available on clinicaltrials.gov. This study was first posted on September 16th 2020 and was last edited 14th September 2022. The research is looking for 30 individuals from 5 different locations."
Is this study novel in any way?
"Since 2014, Benralizumab has undergone clinical trials. The first one was completed in that same year and sponsored by AstraZeneca. This initial study only had 20 participants. Phase 2 & 3 drug approval was given after the successful completion of the trial. As of now, there are 20 active trials being conducted for Benralizumab in 352 cities across 42 countries."
Share this study with friends
Copy Link
Messenger